{"id":"NCT02369874","sponsor":"AstraZeneca","briefTitle":"Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer","officialTitle":"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-09","primaryCompletion":"2018-09-10","completion":"2020-11-13","firstPosted":"2015-02-24","resultsPosted":"2019-10-03","lastUpdate":"2021-02-10"},"enrollment":736,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN"],"interventions":[{"type":"DRUG","name":"MEDI4736","otherNames":[]},{"type":"DRUG","name":"MEDI4736 + Tremelimumab","otherNames":[]},{"type":"DRUG","name":"Standard of Care","otherNames":[]}],"arms":[{"label":"MEDI4736","type":"EXPERIMENTAL"},{"label":"MEDI4736 + Tremelimumab","type":"EXPERIMENTAL"},{"label":"Standard of Care","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"September 2015 to September 2018 (36 months)","effectByArm":[{"arm":"Durvalumab + Tremelimumab","deltaMin":6.5,"sd":null},{"arm":"Durvalumab","deltaMin":7.6,"sd":null},{"arm":"Standard of Care (SoC)","deltaMin":8.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.7624"},{"comp":"OG001 vs OG002","p":"0.1993"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":168,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Chile","Croatia","Czechia","France","Georgia","Germany","Hungary","Israel","Italy","Japan","Poland","Romania","Russia","Serbia","South Korea","Spain","Taiwan","Ukraine"]},"refs":{"pmids":["32294530"],"seeAlso":["http://www.emergingmed.com/networks/AstraZeneca"]},"adverseEventsSummary":{"seriousAny":{"events":79,"n":246},"commonTop":["Anaemia","Asthenia","Decreased appetite","Fatigue","Nausea"]}}